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P2Y12 Inhibition in Patients with NSTEMI — Can Later Be Better?
John F. Keaney, Jr., M.D.
Acute coronary syndrome is an umbrella term 
that is used to describe the abrupt reduction of 
blood flow to myocardial tissue, typically associ-
ated with the rupture of a coronary atheroscle-
rotic plaque. Rupture exposes the blood to plaque 
contents, resulting in the deposition and activa-
tion of platelets and the formation of thrombi. 
Complete thrombotic occlusion produces ST-
segment elevation myocardial infarction, whereas 
incomplete impairment of coronary blood flow 
results in unstable angina or, when biomarkers 
for myocardial injury are present, non–ST-segment 
elevation myocardial infarction (NSTEMI). Be-
cause the rupture of a plaque incites platelet ac-
tivation and thrombosis, treatments for unstable 
angina and NSTEMI have focused on inhibiting 
platelet function and the coagulation cascade. In 
patients at high risk for future events (i.e., re-
infarction or recurrent ischemia), an early invasive 
strategy of cardiac catheterization and revascu-
larization is recommended, and in most of these 
patients intracoronary stents are implanted to 
treat the plaque rupture. Since stents can produce 
further plaque trauma, platelet-dependent throm-
bosis, and embolization into the coronary micro-
circulation, it is best practice to treat patients 
with agents that inhibit platelet activation to 
prevent recurrent ischemia after percutaneous 
coronary intervention (PCI). As a consequence, 
current guidelines recommend dual antiplatelet 
therapy with aspirin plus another agent in pa-
tients with NSTEMI who are undergoing PCI.1,2
Among the agents available to complement 
aspirin are three approved inhibitors of the 
platelet P2Y12 receptor — clopidogrel, prasugrel, 
and ticagrelor — that are known to reduce is-
chemic events in patients with NSTEMI who are 
undergoing PCI.3-5 Despite this proven efficacy, 
our knowledge about the administration of dual 
antiplatelet therapy remains incomplete. For ex-
ample, the timing for starting P2Y12 inhibition is 
not clear. In one pivotal trial, patients were 
treated for several days to weeks before revascu-
larization,6 whereas other trials involved treat-
ment around the time of cardiac catheteriza-
tion.4,5 Guidelines recommend that clopidogrel 
be administered soon after hospital admission,1,2 
but this recommendation has, to my knowledge, 
never been tested directly in a randomized trial. 
The trial data for the second-generation agents, 
prasugrel and ticagrelor, are more limited than 
are those for clopidogrel and have not specifi-
cally tested this question.
Montalescot and colleagues7 offer new insight 
into the timing of prasugrel administration in 
patients with NSTEMI who are scheduled to un-
dergo catheterization. In their study, now report-
ed in the Journal, they randomly assigned 4033 
patients to receive prasugrel as pretreatment (2 to 
48 hours before cardiac catheterization) or to 
receive prasugrel after catheterization if PCI was 
planned. They found that pretreatment with 
prasugrel clearly provided better inhibition of 
platelet function at the time of catheterization. 
However, the pretreatment strategy as compared 
with the late-administration strategy had no sig-
nificant effect on the rate of major ischemic 
events over the course of the 30-day study period. 
In fact, the trial was terminated because prasu-
grel pretreatment produced harm, with more 
bleeding events that were categorized as major 
or life-threatening.
The findings of Montalescot and coworkers 
highlight the difference between first-generation 
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and second-generation P2Y12 inhibitors. Clopid-
ogrel produces irreversible, but sometimes in-
complete, P2Y12 inhibition through conversion 
of the drug to an active metabolite. Clopidogrel 
is typically administered well before PCI, since 
this strategy appears to ensure adequate platelet 
inhibition at the time of PCI and is the most ef-
fective strategy for reducing ischemic events.8 Pra-
sugrel, although also a prodrug, undergoes more 
efficient metabolism, producing faster and more 
complete platelet inhibition,9 thus obviating the 
need for pretreatment. In the study by Montale-
scot et al., pretreatment with prasugrel afforded 
maximal platelet inhibition at the time of vascu-
lar access, which explains why excess procedure-
related bleeding was observed. Overall, these 
results indicate that patients with NSTEMI who 
are selected for an early invasive strategy will 
be best served by administration of prasugrel 
only after angiographic definition of their cor-
onary anatomy. It remains to be seen whether 
a similar strategy could be applied to ticagrelor, 
the other high-potency P2Y12 antagonist cur-
rently available.
The work by Montalescot and colleagues may 
streamline the care of patients with NSTEMI in 
the hospital. Up to 16% of patients with NSTEMI 
ultimately undergo coronary-artery bypass graft-
ing (CABG).3 Because current guidelines recom-
mend P2Y12 inhibition soon after hospital ad-
mission, many patients with NSTEMI who need 
CABG will have received P2Y12 antagonists be-
fore the catheterization. Administration of P2Y12 
inhibitors within 5 days before CABG has been 
linked to excess bleeding3 and prolonged hospi-
talization,10 prompting recommendations that 
CABG be delayed until 5 to 7 days after discon-
tinuation of P2Y12 antagonists.1,2 As a conse-
quence, early P2Y12-inhibition therapy is an im-
portant cause of delay in performing CABG, 
adding inefficiency and cost to the care of pa-
tients with NSTEMI. However, the work of 
Montalescot and coworkers indicates that one 
can safely pursue a more parsimonious approach 
of reserving prasugrel administration until after 
angiography. With this strategy, P2Y12 treatment 
can be limited to patients who will be undergo-
ing PCI, and patients with NSTEMI who require 
CABG will be able to avoid unnecessary delays. 
Further studies will be needed to determine 
whether newer agents, administered only after 
angiography, can improve the efficiency of car-
ing for patients with NSTEMI.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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